eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

mob-img

ELIQUIS (apixaban) resources for healthcare professionals

Checklist to use when prescribing
ELIQUIS to patients with NVAF


checklist-image

To download and print, click here.


Checklist to use when prescribing
ELIQUIS to patients with DVT / PE


checklist-image

To download and print, click here.

CHECKLIST TO USE WHEN PRESCRIBING
ELIQUIS TO PATIENTS WITH NVAF SWITCHING FROM WARFARIN


checklist-image

To download and print, click here.


ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor indicated for:

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (New York Heart Association Class ≥II)1
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
TIA = transient ischaemic attack    
VTE = Venous Thromboembolic Events

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.